Alpha-synuclein

Alpha-synuclein is a presynaptic neuronal protein that, when misfolded, aggregates into toxic clumps known as Lewy bodies, playing a central role in the development of Parkinson's disease and related neurodegenerative disorders.

Found abundantly in the human brain, alpha-synuclein is primarily localized at the tips of nerve cells, known as presynaptic terminals. While its exact physiological role remains a subject of ongoing scientific investigation, it is widely believed to help regulate the release of neurotransmitters—particularly dopamine—by interacting with synaptic vesicles. The protein is encoded by the SNCA gene, and in its healthy state, it exists as a soluble, unfolded molecule that facilitates normal neuronal communication.

However, in certain pathological states, alpha-synuclein undergoes a dramatic structural transformation. The protein misfolds and begins to clump together, first forming small, toxic clusters called oligomers, and eventually assembling into large, insoluble fibrils. These dense accumulations are the primary structural components of Lewy bodies and Lewy neurites, which disrupt cellular function and ultimately lead to neuronal death.

Emerging research suggests that misfolded alpha-synuclein may behave in a "prion-like" manner. This means that the abnormal protein can potentially spread from one neuron to another, corrupting healthy alpha-synuclein proteins along the way and propagating the disease pathology throughout the nervous system over years or decades.

The study of alpha-synuclein is a cornerstone of modern neurobiology, specifically within the study of protein-misfolding diseases. Just as amyloid-beta and tau are central to Alzheimer's disease, alpha-synuclein is the defining feature of a group of conditions collectively known as "synucleinopathies." This category includes Parkinson's disease, Lewy body dementia (LBD), and multiple system atrophy (MSA). Researchers study the SNCA gene closely, as both mutations and multiplications of this gene are known causes of familial (inherited) Parkinson's disease.

For patients and the medical community, alpha-synuclein represents the most critical biomarker and therapeutic target for Parkinson's disease. Because the clumping of this protein begins years before motor symptoms appear, detecting misfolded alpha-synuclein is revolutionizing early diagnosis. Advanced diagnostic tools, such as seed amplification assays (using cerebrospinal fluid or skin biopsies), can now identify the presence of the abnormal protein with high accuracy. Furthermore, experimental disease-modifying therapies—including monoclonal antibodies and small molecules—are currently being developed and tested with the specific goal of halting or clearing alpha-synuclein aggregates, offering hope for treatments that can slow or stop the progression of synucleinopathies.